drugset
drugset / Trial / NCT04261426

The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia

NCT04261426 ↗

Phase 2/3 Unknown 80 enrolled Peking Union Medical College Hospital Tongji Hospital · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

In this single-center, randomized, open-label, controlled study, the investigators will evaluate the efficacy and safety of Intravenous Immunoglobulin (IVIG) in combination with standard care for severe 2019 novel coronavirus (2019-nCoV) pneumonia.

Timeline

Start
2020-02-10
Primary completion
2020-04-30
Completion
2020-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 0.5 g/kg Intravenous

Indications

COVID-19